Clinical Trials

New Treatment Options, Close to Home

Clinical trials are how new treatments and better outcomes are developed. Since 2016, our Research Department has offered oncology and hematology trials to patients right here on the Northshore.

See open trials Our past research
  • Since 2016Running clinical trials for our patients
  • Phase II to IVTrials offered at our Covington and Hammond offices
  • Cancer and blood disordersStudies in both oncology and hematology

How Clinical Trials Work

Our Research Department runs clinical trials in both oncology and hematology. In each trial, a new experimental medication, or a new way of using an existing one, is compared with the treatments available today to advance cancer care for patients around the world.

Every trial has criteria a patient must meet to take part. These guidelines help protect the safety of each patient.

We strive to give you as many treatment options as possible. Only you and your doctor can decide whether a clinical trial is right for you.

  1. Phase IFinding a safe dose of a new medication and studying its safety.
  2. Phase IIFurther study of safety and how well the treatment works.
  3. Phase IIIComparing the new treatment with medications available today.
  4. Phase IVFurther study of medications already approved by the FDA.

PCC offers Phase II, III and IV trials at our Covington and Hammond offices.

About our research program

Pontchartrain Cancer Center has taken part in clinical trials since 2016. Our Research Department works alongside your physician and care team, so you can join a study without leaving the doctors you know or traveling far from home.

Cancer research is always evolving, and new treatments emerge every year. Our research program helps PCC stay at the leading edge of cancer care, and over the years our patients have taken part in studies of breast, lung, colorectal, prostate and many other cancers, as well as blood disorders.

What is clinical research?

Clinical research studies how new medications, tests and approaches work in people. Each study follows a detailed plan, called a protocol, that spells out who can join, what treatment or testing is involved, and how participants are monitored.

Before you join, the research team will walk you through the study, including its possible benefits and risks, and answer your questions. This process is called informed consent. Some studies test a new treatment, while others study blood tests, collect samples or follow how patients do on approved treatments.

Why participate in clinical research?

Patients choose to take part in clinical trials for many reasons:

  • Access to new treatments that are not yet widely available
  • Close monitoring by your care team and our research staff throughout the study
  • Helping doctors find better treatments for future patients

Taking part is always your choice, and you can leave a study at any time. Talk with your PCC doctor about whether a trial fits your diagnosis and goals.

For more information on clinical trials, visit ClinicalTrials.gov.

Now enrolling

Open to Enrollment

These studies are currently enrolling. Ask your PCC doctor whether one might be right for you.

Now enrolling Lung CancerPhase 3

ARTEMIA

For people with HLA-A2 positive non-small cell lung cancer that has stopped responding to immunotherapy.

A Randomized, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 versus Docetaxel in HLA-A2 Positive Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) and Secondary Resistance to Immune Checkpoint Inhibitors (ICI)

View on ClinicalTrials.gov (NCT06472245)

Now enrolling Lung CancerPhase 3

HARMONi-7

For people starting their first treatment for metastatic non-small cell lung cancer with high PD-L1 (over 50%).

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab vs Pembrolizumab for the First-line Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 (>50%) Expression

View on ClinicalTrials.gov (NCT06767514)

Now enrolling Lung CancerPhase 3

Symbiotic Lung-01

For adults with locally advanced or metastatic non-small cell lung cancer.

A Phase 3, Double-blind, Randomized Study to Investigate Tolerability, PK and Anti-tumor Efficacy of PF-08634404 (SSGJ-707) in Combination with Chemotherapy vs Pembrolizumab in Combination with Chemotherapy in Adult Participants with Locally Advanced or Metastatic NSCLC

View on ClinicalTrials.gov (NCT07222566)

Now enrolling HematologyPhase 2

VAY2EXPLORE

For adults with primary immune thrombocytopenia (ITP) who have already had at least one treatment.

An Exploratory Study to Evaluate the Safety and Tolerability of Investigator's Choice Thrombopoietin Receptor Agonist (TPO-RA) with Ianalumab (VAY736) in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least One Line of Therapy

View on ClinicalTrials.gov (NCT07421167)

Now enrolling Solid TumorsObservational

FH-PrwS-07-002

Studies blood tests that look for traces of cancer left after treatment (molecular residual disease) in many tumor types.

Flatiron Health Pan-tumor MRD Study

View on ClinicalTrials.gov (NCT06605404)

Now enrolling Solid TumorsObservational

BTO NS005

Studies the NorthStar Response blood test for detecting traces of cancer left after treatment (molecular residual disease).

NorthStar Response MRD Comparison Study

Now enrolling Solid TumorsObservational

BTO NS006

Studies the NorthStar Response blood test as a way to monitor how well immunotherapy is working.

NorthStar Response for Immune Checkpoint Inhibitor (ICI) Treatment Response Monitoring

Now enrolling Solid TumorsObservational

BESPOKE Pan Cancer

Open to any cancer type. Studies a blood test for detecting and monitoring molecular residual disease.

Molecular Residual Disease Detection and Monitoring in Any Cancer